The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

Connor Schoen, the leader of homelessness nonprofit Breaktime, engineered a $6.3 million deal to purchase the five-story ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...

But in 2025, Moderna aims to reduce cash cost expenses by $1 billion, CEO Stéphane Bancel said at the J.P. Morgan Healthcare Conference in January. The company will report its 2024 full-year ...